Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Sage's depression drug improves symptoms, but durability concerns sink shares

Economy Feb 16, 2022 11:55AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A test tube is seen in front of displayed Biogen logo in this illustration taken, December 1, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

By Amruta Khandekar

(Reuters) - Sage Therapeutics Inc's drug helped improve depressive symptoms after three days in a late-stage study, but investor concerns over how long the treatment's effect would last sent the drug developer's shares down 17% on Wednesday.

In a study among 440 patients with major depressive disorder, the drug, zuranolone, taken along with an antidepressant also showed a statistically significant improvement in symptoms over a two-week period, the company and partner Biogen Inc (NASDAQ:BIIB) said on Wednesday.

Analysts, however, said the near-term durability of the oral drug would likely be the key to broader commercial success.

"The clinical benefit is modest and the effects are not durable," said Truist Securities analyst Joon Lee, adding that the regulatory process for the drug is likely to be "wrought with noise, controversy" over the next 12-18 months.

The trial results come after a separate late-stage trial in June raised similar concerns about how long the symptom improvement would last.

Major depressive disorder affects over 16 million American adults every year and is mainly treated with antidepressants, which could take up to six weeks to show effect.

Sage, which has a postpartum depression drug on the market, said it plans to file for U.S. approval of the drug this year. Sage signed a deal worth up to $1.5 billion with Biogen in 2020 to develop zuranolone along with another experimental drug.

While zuranolone showed greater reduction in symptoms than placebo after three days, the difference was still lower than Street expectations, Guggenheim analyst Yatin Suneja said.

But Suneja added that the drug remains approvable and he had expected its effect to wane over time as the company had decided to evaluate the results at day three for the main goal instead of at day fifteen as it had done in the June trial.

Sage's depression drug improves symptoms, but durability concerns sink shares
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email